These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

435 related articles for article (PubMed ID: 32941897)

  • 1. Application and reflection of genomic scar assays in evaluating the efficacy of platinum salts and PARP inhibitors in cancer therapy.
    Gou R; Dong H; Lin B
    Life Sci; 2020 Nov; 261():118434. PubMed ID: 32941897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical assays for assessment of homologous recombination DNA repair deficiency.
    Stover EH; Fuh K; Konstantinopoulos PA; Matulonis UA; Liu JF
    Gynecol Oncol; 2020 Dec; 159(3):887-898. PubMed ID: 33012552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Homologous recombination deficiency real-time clinical assays, ready or not?
    Fuh K; Mullen M; Blachut B; Stover E; Konstantinopoulos P; Liu J; Matulonis U; Khabele D; Mosammaparast N; Vindigni A
    Gynecol Oncol; 2020 Dec; 159(3):877-886. PubMed ID: 32967790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarkers for Homologous Recombination Deficiency in Cancer.
    Hoppe MM; Sundar R; Tan DSP; Jeyasekharan AD
    J Natl Cancer Inst; 2018 Jul; 110(7):704-713. PubMed ID: 29788099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular signatures of BRCAness analysis identifies PARP inhibitor Niraparib as a novel targeted therapeutic strategy for soft tissue Sarcomas.
    Li H; Tu J; Zhao Z; Chen L; Qu Y; Li H; Yao H; Wang X; Lee DF; Shen J; Wen L; Huang G; Xie X
    Theranostics; 2020; 10(21):9477-9494. PubMed ID: 32863940
    [No Abstract]   [Full Text] [Related]  

  • 6. Role of Poly (ADP-Ribose) Polymerase inhibitors beyond BReast CAncer Gene-mutated ovarian tumours: definition of homologous recombination deficiency?
    Gourley C; Miller RE; Hollis RL; Ledermann JA
    Curr Opin Oncol; 2020 Sep; 32(5):442-450. PubMed ID: 32796232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient Assessment and Therapy Planning Based on Homologous Recombination Repair Deficiency.
    Li W; Gao L; Yi X; Shi S; Huang J; Shi L; Zhou X; Wu L; Ying J
    Genomics Proteomics Bioinformatics; 2023 Oct; 21(5):962-975. PubMed ID: 36791952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Testing for homologous recombination repair or homologous recombination deficiency for poly (ADP-ribose) polymerase inhibitors: A current perspective.
    Herzog TJ; Vergote I; Gomella LG; Milenkova T; French T; Tonikian R; Poehlein C; Hussain M
    Eur J Cancer; 2023 Jan; 179():136-146. PubMed ID: 36563604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Homologous recombination repair deficiency as a predictive biomarker : Basic mechanisms and detection methods].
    Pfarr N; Merkelbach-Bruse S
    Pathologe; 2021 Jul; 42(4):391-398. PubMed ID: 34152463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PARP Inhibitors and the Evolving Landscape of Ovarian Cancer Management: A Review.
    Cook SA; Tinker AV
    BioDrugs; 2019 Jun; 33(3):255-273. PubMed ID: 30895466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [BRCA1 and BRCA2 - pathologists starting kit].
    Škapa P
    Cesk Patol; 2016; 52(4):193-196. PubMed ID: 27869444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Homologous recombination deficiency and ovarian cancer.
    Ledermann JA; Drew Y; Kristeleit RS
    Eur J Cancer; 2016 Jun; 60():49-58. PubMed ID: 27065456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers.
    Watkins JA; Irshad S; Grigoriadis A; Tutt AN
    Breast Cancer Res; 2014 Jun; 16(3):211. PubMed ID: 25093514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRCAness, Homologous Recombination Deficiencies, and Synthetic Lethality.
    Murai J; Pommier Y
    Cancer Res; 2023 Apr; 83(8):1173-1174. PubMed ID: 37057596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Abnormalities of DNA repair and gynecological cancers].
    Auguste A; Leary A
    Bull Cancer; 2017 Nov; 104(11):971-980. PubMed ID: 29054544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional RECAP (REpair CAPacity) assay identifies homologous recombination deficiency undetected by DNA-based BRCAness tests.
    Meijer TG; Nguyen L; Van Hoeck A; Sieuwerts AM; Verkaik NS; Ladan MM; Ruigrok-Ritstier K; van Deurzen CHM; van de Werken HJG; Lips EH; Linn SC; Memari Y; Davies H; Nik-Zainal S; Kanaar R; Martens JWM; Cuppen E; Jager A; van Gent DC
    Oncogene; 2022 Jun; 41(26):3498-3506. PubMed ID: 35662281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utility of Homologous Recombination Deficiency Biomarkers Across Cancer Types.
    Takamatsu S; Brown JB; Yamaguchi K; Hamanishi J; Yamanoi K; Takaya H; Kaneyasu T; Mori S; Mandai M; Matsumura N
    JCO Precis Oncol; 2021 Aug; 5():. PubMed ID: 34423229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Homologous Recombination Deficiency (HRD) in Cutaneous Oncology.
    Akinjiyan FA; Morecroft R; Phillipps J; Adeyelu T; Elliott A; Park SJ; Butt OH; Zhou AY; Ansstas G
    Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The current status of PARP inhibitors in ovarian cancer.
    McLachlan J; George A; Banerjee S
    Tumori; 2016 Oct; 102(5):433-440. PubMed ID: 27716873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BET proteins regulate homologous recombination-mediated DNA repair: BRCAness and implications for cancer therapy.
    Mio C; Gerratana L; Bolis M; Caponnetto F; Zanello A; Barbina M; Di Loreto C; Garattini E; Damante G; Puglisi F
    Int J Cancer; 2019 Feb; 144(4):755-766. PubMed ID: 30259975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.